NeuroPace, Inc. reported record quarterly revenue of $22.5 million for the first quarter of 2025, marking a 24% increase from $18.1 million in the same period the previous year. The growth was primarily driven by a 26% year-over-year increase in RNS System revenue. The company's gross margin for the quarter was 77.0%, surpassing the high end of its full-year guidance range. NeuroPace also elevated its full-year 2025 revenue guidance to a range of $93 million to $97 million, indicating projected growth of 16% to 21% compared to $79.9 million in 2024. In terms of expenses, total operating expenses are projected to range between $92 million and $95 million for the full year, with an estimated $11 million attributed to stock-based compensation. NeuroPace has made significant strides in its Project CARE initiative, noting an increase in total implants and referrals compared to the fourth quarter of 2024. Additionally, the company presented positive 3-year data from the ongoing Post-Approval Study of the RNS System in adults with drug-resistant focal epilepsy, illustrating best-in-class efficacy results with an 82% median reduction in seizures over three years and 42% of patients remaining seizure-free for six months or longer. NeuroPace continues to focus on expanding RNS therapy and advancing product development in its pursuit of sustained revenue growth and long-term value creation.